CoaguChek® XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome

被引:7
作者
Fonseca, Maria Ester S. [1 ]
Balbi, Gustavo G. M. [1 ,2 ]
Signorelli, Flavio [1 ,3 ]
Gouvea, Christiane P. [4 ]
de Andrade, Danieli C. O. [1 ]
机构
[1] Univ Sao Paulo, Rheumatol Div, Sao Paulo, Brazil
[2] Univ Fed Juiz de Fora UFJF, Rheumatol Div, Juiz De Fora, Brazil
[3] Univ Estado Rio de Janeiro UERJ, Rheumatol Div, Rio De Janeiro, Brazil
[4] Univ Sao Paulo, Cent Inst, Coagulat Div, Sao Paulo, Brazil
关键词
CoaguChek XS; prothrombin time; point-of-care; international normalized ratio; anticoagulation; warfarin; vitamin K antagonist; antiphospholipid syndrome; antiphospholipid antibodies; VITAMIN-K ANTAGONISTS; LUPUS ANTICOAGULANT; CLASSIFICATION CRITERIA; INTERNATIONAL SOCIETY; RECURRENT THROMBOSIS; GUIDELINES; INR; ANTIBODIES; MANAGEMENT; UPDATE;
D O I
10.1177/09612033221086134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The standard of care for thrombotic antiphospholipid syndrome (APS) is anticoagulation with vitamin K antagonists (VKAs). Prothrombin time, and its corresponding international normalized ratio (INR), is the laboratory test routinely performed to assess anticoagulation. Self-management of VKA therapy using point-of-care (POC) devices seems to be an attractive option. Purpose/objective: To evaluate the accuracy of a POC device (CoaguChek XS) in APS patients by comparing it with venous laboratory INR. Furthermore, we analyzed whether other clinical and laboratory features could interfere with the CoaguChek XS results. Patients and methods: This is a single-center cross-sectional study with 94 APS patients from a tertiary rheumatology clinic performed from August 2014 to March 2015. The comparison between CoaguChek XS and venous laboratory INR results was evaluated using the coefficient of determination (r) followed by the Bland-Altman test. A paired t-test was also applied. A difference of up to +/- 0.5 INR unit between the two systems was considered clinically acceptable. Results: The mean CoaguChek-INR was 2.94 +/- 1.41 and venous laboratory INR was 2.43 +/- 0.86, with a correlation coefficient (r) of 0.95. Categorizing I NR values in ranges (INR <2, INR 2-3, I NR 3-4, and I NR >4), we found that the INR >4 group presented a lower correlation (r = 0.64) compared to the other ranges (p < 0.05). Although both methods were highly correlated, CoaguChek XS showed higher values than the venous laboratory INR, with an increased average of 0.42 +/- 0.54. Therefore, we proposed a simple linear regression model to predict the venous laboratory INR values, using results obtained from CoaguChek XS. A difference <= 0.5 INR unit between the two systems was observed in 57.4% of patients, and the aPL profile did not influence the results. Conclusion: Although CoaguChek XS and venous laboratory INR demonstrated a good linear correlation in the group of INR <= 4, extra caution should be taken in APS patients, since a reasonable proportion of patients can present differences in INR results that are not acceptable. We do not recommend routine POC in APS patients.
引用
收藏
页码:565 / 574
页数:10
相关论文
共 50 条
[21]   14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends [J].
Erkan, Doruk ;
Aguiar, Cassyanne L. ;
Andrade, Danieli ;
Cohen, Hannah ;
Cuadrado, Maria J. ;
Danowski, Adriana ;
Levy, Roger A. ;
Ortel, Thomas L. ;
Rahman, Anisur ;
Salmon, Jane E. ;
Tektonidou, Maria G. ;
Willis, Rohan ;
Lockshin, Michael D. .
AUTOIMMUNITY REVIEWS, 2014, 13 (06) :685-696
[22]   A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome(WAPS) [J].
Finazzi, G ;
Marchioli, R ;
Brancaccio, V ;
Schinco, P ;
Wisloff, F ;
Musial, J ;
Baudo, F ;
Berrettini, M ;
Testa, S ;
D'Angelo, A ;
Tognoni, G ;
Barbui, T .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) :848-853
[23]   An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation [J].
Fitzmaurice, DA ;
Gardiner, C ;
Kitchen, S ;
Mackie, I ;
Murray, ET ;
Machin, SJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :156-165
[24]   Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature [J].
Galli, M ;
Luciani, D ;
Bertolini, G ;
Barbui, T .
BLOOD, 2003, 101 (05) :1827-1832
[25]   Diagnosis and Management of the Antiphospholipid Syndrome [J].
Garcia, David ;
Erkan, Doruk .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :2010-2021
[26]   Self-monitoring of oral anticoagulation: a systematic review and meta-analysis [J].
Heneghan, C ;
Alonso-Coello, P ;
Garcia-Alamino, JM ;
Perera, R ;
Meats, E ;
Glasziou, P .
LANCET, 2006, 367 (9508) :404-411
[27]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[28]   Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome [J].
Isert, Mecki ;
Miesbach, Wolfgang ;
Schuettfort, Gundolf ;
Weil, Yvonne ;
Tirneci, Vanessa ;
Kasper, Alexander ;
Weber, Adele ;
Lindhoff-Last, Edelgard ;
Herrmann, Eva ;
Linnemann, Birgit .
ANNALS OF HEMATOLOGY, 2015, 94 (08) :1291-1299
[29]   External quality assessment (EQA) for CoaguChek monitors [J].
Jespersen, Joergen ;
Poller, Leon ;
van den Besselaar, A. M. H. P. ;
van der Meer, Felix J. M. ;
Palareti, Gualtiero ;
Tripodi, Armando ;
Shiach, Caroline ;
Keown, Michelle ;
Ibrahim, Saied .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (05) :936-941
[30]   Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy [J].
Jonsson, M ;
Hillarp, A ;
Svensson, P .
THROMBOSIS RESEARCH, 2004, 114 (02) :83-89